On-demand education
Filter
FILTER BY TESTS
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Do largest basal tumor diameter and the American Joint Committee on Cancer’s cancer staging influence prognostication by gene expression profiling in choroidal melanoma. Am J Ophthalmol 2018 Nov;195:83–92.

DecisionDx-UM
Authors: Demirci H, Niziol LM, Ozkurt Z, Slimani N, Ozgonul C, Liu T, et al.
Prognostic
Ophthalmology

Driver mutations in uveal melanoma: associations with gene expression profile and patient outcomes. JAMA Ophthalmol 2016;134:728-33.

DecisionDx-UM
Authors: Decatur CL, Ong E, Garg N, et al.
Prognostic
Ophthalmology

Current clinical practice: differential management of uveal melanoma in the era of molecular tumor analyses.

DecisionDx-UM
Authors: Aaberg TM, Cook RW, Oelschlager KM, et al.
Prognostic
Ophthalmology

Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4. Oncotarget 2016;7:4624-31.

DecisionDx-UM
Authors: Johansson P, Aoude LG, Wadt K, et al.
Prognostic
Ophthalmology

Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in Class 1 and 2 uveal melanomas. Oncotarget 2016;7(37): 59209-19.

DecisionDx-UM
Authors: Field MG, Durante MA, Decatur CL, et al.
Prognostic
Ophthalmology

TissueCypher® Objectively Risk Stratifies Barrett’s Esophagus Patients with Low-Grade Dysplasia*

Pathologic diagnosis is highly variable, even among experts, while TissueCypher® provides objective risk stratification. TissueCypher outperformed community and expert pathologists for sensitivity and detected >50% of NDBE progressors who were down-staged (i.e. missed).
TissueCypher
Barrett's Esophagus
Authors: Nicola Frei, Doctor of Medicine, Amsterdam UMC
Prognostic
Gastroenterology
Webinar

Chromosome 3 status combined with BAP1 and EIF1AX mutation profiles are associated with metastasis in uveal melanoma. Invest Ophthalmol Vis Sci 2014;55:5160-7.

DecisionDx-UM
Authors: Ewens KG, Kanetsky PA, Richards-Yutz J, et al.
Prognostic
Ophthalmology

Clinical characteristics of uveal melanoma in patients with germline BAP1 mutations. JAMA Ophthalmol 2015;133:881-7.

DecisionDx-UM
Authors: Gupta MP, Lane AM, DeAngelis MM, et al.
Prognostic
Ophthalmology

Collaborative Ocular Oncology Group Report Number 1: Prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology 2012;119: 1596-1603.

DecisionDx-UM
Authors: Onken MD, Worley LA, Char CH, et al
Prognostic
Ophthalmology

An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. J Mol Diagn 2010;12(4):461-8.

DecisionDx-UM
Authors: Onken MD, Worley LA, Tuscan MD, et al.
Prognostic
Ophthalmology

Clinical performance and management outcomes with the DecisionDx-UM gene expression profile test in a prospective multicenter study. J Oncol 2016; doi:10.1155/2016/5325762.

DecisionDx-UM
Authors: Plasseraud KM, Cook RW, Tsai T, et al.
Prognostic
Ophthalmology

Learn About Castle’s Comprehensive Diagnostic Offering

Our suite of highly accurate tests for melanocytic lesions of uncertain potential increases diagnostic confidence and enables better clinical management plans for patients. Learn the essentials from this comprehensive introduction by Matthew Goldberg, MD, Medical Director for Castle Biosciences.
MyPath Melanoma
DiffDx-Melanoma
Cutaneous Melanoma
Authors: Matthew Goldberg, MD
Diagnostic
Dermatology